K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · NOVO NORDISK INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-22 | NVO | NOVO NORDISK INC. | PUBLIC STRATEGIES WASHINGTON, INC. | $10K | |
| 2026-04-20 | NVO | NOVO NORDISK INC. | NOVO NORDISK INC. | $1.3M | Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation and drug pricing legislation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around drug pricing S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding International and corporate tax issues Tariffs and trade policy |
| 2026-04-20 | NVO | NOVO NORDISK INC. | THE NICKLES GROUP, LLC | $80K | Issues related to compounding and counterfeit drugs. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax. Issues related to tariffs. Issues related to importation of counterfeit drugs. |
| 2026-04-20 | NVO | NOVO NORDISK INC. | NVG, LLC | $80K | Issues related to Medicare coverage of Anti-Obesity Medicines. Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines. |
| 2026-04-20 | NVO | NOVO NORDISK INC. | WILLIAMS AND JENSEN, PLLC | $60K | Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. Support for obesity drug coverage and access. Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Issues related to corporate tax and international tax including related domestic and international tax issues for reconciliation legislation; monitor implementation of PL 119-21. General issues related to patent protections. |
| 2026-04-20 | NVO | NOVO NORDISK INC. | TODD STRATEGY GROUP | $60K | Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform. Health care supply chain. 340B. Treat and Reduce Obesity Act. |
| 2026-04-20 | NVO | NOVO NORDISK INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, medication affordability and access, general diabetes prevention, obesity, impacts of drug shortages, drug supply chain Treat and Reduce Obesity Act, obesity treatment Federal budget issues |
| 2026-04-20 | NVO | NOVO NORDISK INC. | AVOQ, LLC | $20K | Issues related to obesity; Issues related to medication affordability and access |
| 2026-04-17 | NVO | NOVO NORDISK INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $80K | Issues related to general compounding. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding. Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973). Issues related to general compounding. |
| 2026-04-17 | NVO | NOVO NORDISK INC. | S-3 GROUP | $20K | Issues related to compounding and counterfeit drugs. Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing. Issues related to tariffs and importation of counterfeit drugs. |
| 2026-04-16 | NVO | NOVO NORDISK INC. | BALLARD PARTNERS | $120K | Guidance regarding pharmaceutical regulations. |
| 2026-04-15 | NVO | NOVO NORDISK INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Issues related to anti-obesity medications, drug pricing, and pharmaceutical supply chain. |
| 2026-04-10 | NVO | NOVO NORDISK INC. | HOLLAND & KNIGHT LLP | $60K | Legislation related to obesity treatments; Advocacy for antiobesity medications. Legislation related to obesity treatments; Advocacy for antiobesity medications. |
| 2026-04-07 | NVO | NOVO NORDISK INC. | S-3 GROUP | $0 | Issues related to compounding and counterfeit drugs; drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharamcy benefit management reforms; Most Favored Nation drug pricing; tariffs; importation of counterfeit drugs. Issues related to compounding and counterfeit drugs; drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharamcy benefit management reforms; Most Favored Nation drug pricing; tariffs; importation of counterfeit drugs. Issues related to compounding and counterfeit drugs; drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharamcy benefit management reforms; Most Favored Nation drug pricing; tariffs; importation of counterfeit drugs. |
| 2026-01-20 | NVO | NOVO NORDISK INC. | NOVO NORDISK INC. | $2.1M | Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around Most Favored Nation drug pricing S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding International and corporate tax, H.R. 1 One Big Beautiful Bill Discussed potential tariffs. |
| 2026-01-20 | NVO | NOVO NORDISK INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Issues related to anti-obesity medications, drug pricing, and pharmaceutical supply chain. |
| 2026-01-20 | NVO | NOVO NORDISK INC. | THE NICKLES GROUP, LLC | $80K | Issues related to compounding and counterfeit drugs. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitor issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations. Issues related to tariffs. Issues related to importation of counterfeit drugs. |
| 2026-01-20 | NVO | NOVO NORDISK INC. | NVG, LLC | $80K | Issues related to Medicare coverage of Anti-Obesity Medicines. Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines. |
| 2026-01-20 | NVO | NOVO NORDISK INC. | WILLIAMS AND JENSEN, PLLC | $60K | Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. Support for obesity drug coverage and access. Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Issues related to corporate tax and international tax including related domestic and international tax issues for reconciliation legislation; monitor implementation of PL 119-21. General issues related to patent protections. |
| 2026-01-20 | NVO | NOVO NORDISK INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, medication affordability and access, general diabetes prevention, obesity, impacts of drug shortages Treat and Reduce Obesity Act, obesity treatment Federal budget issues |
| 2026-01-20 | NVO | NOVO NORDISK INC. | AVOQ, LLC | $60K | Issues related to obesity; Issues related to medication affordability and access |
| 2026-01-20 | NVO | NOVO NORDISK INC. | TODD STRATEGY GROUP | $60K | Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform, Health care supply chain. 340B. Treat and Reduce Obesity Act. |
| 2026-01-20 | NVO | NOVO NORDISK INC. | PUBLIC STRATEGIES WASHINGTON, INC. | $30K | Issues related to the coverage of obesity therapeutics |
| 2026-01-15 | NVO | NOVO NORDISK INC. | BALLARD PARTNERS | $120K | |
| 2026-01-14 | NVO | NOVO NORDISK INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $70K | Issues related to general compounding. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding. Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973). Issues related to general compounding. |
| 2026-01-09 | NVO | NOVO NORDISK INC. | HOLLAND & KNIGHT LLP | $60K | Legislation related to obesity treatments; Advocacy for antiobesity medications. Legislation related to obesity treatments; Advocacy for antiobesity medications. |
| 2025-10-24 | NVO | NOVO NORDISK INC. | PUBLIC STRATEGIES WASHINGTON, INC. | $30K | Issues related to the coverage of obesity therapeutics |
| 2025-10-20 | NVO | NOVO NORDISK INC. | NOVO NORDISK INC. | $1.7M | Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around Most Favored Nation drug pricing S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding International and corporate tax, H.R. 1 One Big Beautiful Bill Discussed potential tariffs. |
| 2025-10-20 | NVO | NOVO NORDISK INC. | NVG, LLC | $100K | Issues related to Medicare coverage of Anti-Obesity Medicines. Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines. |
| 2025-10-20 | NVO | NOVO NORDISK INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, medication affordability and access, general diabetes prevention, obesity, impacts of drug shortages Treat and Reduce Obesity Act, obesity treatment Federal budget issues |
| 2025-10-20 | NVO | NOVO NORDISK INC. | WILLIAMS AND JENSEN, PLLC | $60K | Medication affordability and access; general diabetes prevention, 340B, monitoring FDA reform, changes and new programs. Support for obesity drug coverage and access. Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Issues related to corporate tax and international tax including related domestic and international tax issues considered for reconciliation legislation and H.R. 1, One Big Beautiful Bill Act". General issues related to patent protections. |
| 2025-10-20 | NVO | NOVO NORDISK INC. | AVOQ, LLC | $60K | Issues related to obesity; Issues related to medication affordability and access |
| 2025-10-20 | NVO | NOVO NORDISK INC. | HOLLAND & KNIGHT LLP | $50K | H.R. 1577 - Treat and Reduce Obesity Act of 2021 (117th Cong.). H.R. 1577 - Treat and Reduce Obesity Act of 2021 (117th Cong.). |
| 2025-10-20 | NVO | NOVO NORDISK INC. | PUBLIC STRATEGIES WASHINGTON, INC. | $30K | Issues related to the coverage of obesity therapeutics |
| 2025-10-19 | NVO | NOVO NORDISK INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Issues related to anti-obesity medications, drug pricing, and pharmaceutical supply chain. |
| 2025-10-17 | NVO | NOVO NORDISK INC. | BALLARD PARTNERS | $120K | Guidance regarding pharmaceutical regulations. |
| 2025-10-16 | NVO | NOVO NORDISK INC. | THE NICKLES GROUP, LLC | $80K | Issues related to compounding and counterfeit drugs. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations. Issues related to tariffs. Issues related to importation of counterfeit drugs. |
| 2025-10-15 | NVO | NOVO NORDISK INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $80K | Issues related to the 340B Program. Issues related to general compounding. Issues related to the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding. Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2025 (H.R. 4231 / S. 1973). Issues related to general compounding. |
| 2025-10-12 | NVO | NOVO NORDISK INC. | TODD STRATEGY GROUP | $60K | Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform, Health care supply chain. 340B. Treat and Reduce Obesity Act. |
| 2025-07-21 | NVO | NOVO NORDISK INC. | WILLIAMS AND JENSEN, PLLC | $60K | Medication affordability and access; general diabetes prevention. Pharmacy benefit manager reform proposals. H.R. 1; issues related to biopharmaceutical drug pricing, particularly related to MFN. 340B. Support for obesity drug coverage and access. Treat and Reduce Obesity Act; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169) implementation. Pharmacy benefit manager reform proposals. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. Issues related to corporate tax and international tax including related domestic and international tax issues considered for reconciliation legislation and H.R. 1, One Big Beautiful Bill Act". General issues related to patent protections. |
| 2025-07-21 | NVO | NOVO NORDISK INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, medication affordability and access, general diabetes prevention, obesity Treat and Reduce Obesity Act, obesity treatment Federal budget issues |
| 2025-07-21 | NVO | NOVO NORDISK INC. | AVOQ, LLC | $60K | Issues related to obesity; Issues related to medication affordability and access |
| 2025-07-20 | NVO | NOVO NORDISK INC. | NVG, LLC | $120K | Issues related to Medicare coverage of Anti-Obesity Medicines. Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines. |
| 2025-07-20 | NVO | NOVO NORDISK INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Issues related to anti-obesity medications, drug pricing, and pharmaceutical supply chain. |
| 2025-07-20 | NVO | NOVO NORDISK INC. | TODD STRATEGY GROUP | $60K | Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform, Health care supply chain. 340B. Treat and Reduce Obesity Act. |
| 2025-07-18 | NVO | NOVO NORDISK INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $70K | Issues related to pharmacy benefit managers (PBMs). Issues related to the 340B Program. Issues related to general compounding. Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to general compounding. Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress). Issues related to general compounding. |
| 2025-07-18 | NVO | NOVO NORDISK INC. | THE MADISON GROUP | $60K | Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications, and (4) issues related to compounding and counterfeit drugs. Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications. |
| 2025-07-17 | NVO | NOVO NORDISK INC. | THE NICKLES GROUP, LLC | $80K | Issues related to compounding and counterfeit drugs. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. H.R.1, One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. H.R. 1, One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations. Issues related to tariffs. Issues related to importation of counterfeit drugs. |
| 2025-07-17 | NVO | NOVO NORDISK INC. | HOLLAND & KNIGHT LLP | $50K | H.R. 1577 - Treat and Reduce Obesity Act of 2021 (117th Cong.). H.R. 1577 - Treat and Reduce Obesity Act of 2021 (117th Cong.). |
| 2025-07-17 | NVO | NOVO NORDISK INC. | PUBLIC STRATEGIES WASHINGTON, INC. | $30K | Issues related to the coverage of obesity therapeutics |
| 2025-07-16 | NVO | NOVO NORDISK INC. | NOVO NORDISK INC. | $1.1M | Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding, FDA Agricultural Appropriations bill Obesity, Treat and Reduce Obesity Act, IRA implementation, General engagement around Most Favored Nation drug pricing S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding International and corporate tax, H.R. 1 One Big Beautiful Bill Discussed potential tariffs. |
| 2025-07-16 | NVO | NOVO NORDISK INC. | BALLARD PARTNERS | $40K | Guidance regarding pharmaceutical regulations. |
| 2025-07-01 | NVO | NOVO NORDISK INC. | BALLARD PARTNERS | $0 | Guidance regarding pharmaceutical regulations. |
| 2025-04-21 | NVO | NOVO NORDISK INC. | THE MADISON GROUP | $90K | Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications, and (4) issues related to compounding and counterfeit drugs. Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications. |
| 2025-04-21 | NVO | NOVO NORDISK INC. | CHECKMATE GOVERNMENT RELATIONS | $90K | There is no current bill filed. Issues related to anti-obesity medications, drug pricing, and pharmaceutical supply chain. |
| 2025-04-21 | NVO | NOVO NORDISK INC. | TODD STRATEGY GROUP | $60K | Implementation of Inflation Reduction Act. Pharmacy Benefit Manager Reform. Health care supply chain. 340B. Treat and Reduce Obesity Act. |
| 2025-04-21 | NVO | NOVO NORDISK INC. | WILLIAMS AND JENSEN, PLLC | $60K | General issues related to patent protections. Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158). Support for obesity drug coverage and access. Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. Public Law 118-47. American Relief Act (P.L. 118-158). Issues related to corporate tax and international tax. |
| 2025-04-21 | NVO | NOVO NORDISK INC. | TARPLIN, DOWNS & YOUNG, LLC | $60K | IRA, medication affordability and access, general diabetes prevention, obesity Treat and Reduce Obesity Act, obesity treatment Federal budget issues |
| 2025-04-21 | NVO | NOVO NORDISK INC. | AVOQ, LLC | $60K | Issues related to obesity; Issues related to medication affordability and access |
| 2025-04-19 | NVO | NOVO NORDISK INC. | NVG, LLC | $140K | Issues related to Medicare coverage of Anti-Obesity Medicines. Issues related to pharmaceutical supply chain transparency and integrity. Issues relating to pharmaceutical drug pricing. Issues related to compounding and counterfeit medicines. |
| 2025-04-18 | NVO | NOVO NORDISK INC. | NOVO NORDISK INC. | $2.3M | Obesity, Treat and Reduce Obesity Act, Insulin Pricing/affordability, IRA implementation, supply chain, 340B, Intellectual Property/patent protection, S. 150 - the Affordable Prescriptions for Patients Act, Protect 340B Act, PBM Reform Act, General Compounding Labor-HHS Appropriations Bill, Military Construction, Treat and Reduce Obesity Act, General Compounding Obesity, Treat and Reduce Obesity Act, IRA implementation S. 150, Affordable Prescriptions for Patients Act, Patent Protection, General IP Issues, General Compounding |
| 2025-04-18 | NVO | NOVO NORDISK INC. | ARNOLD & PORTER KAYE SCHOLER LLP | $80K | Issues related to pharmacy benefit managers (PBMs) and the 340B Program. Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability. Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress). |
| 2025-04-17 | NVO | NOVO NORDISK INC. | THE NICKLES GROUP, LLC | $80K | Issues related to compounding and counterfeit drugs. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to the extension of the Tax Cut and Jobs Act provisions impacting corporations. H.R. 591, Defending American Jobs and Investment Act, and H.R. 2423, Unfair Tax Prevention Act, as they relate to multinational corporations. |
| 2025-04-17 | NVO | NOVO NORDISK INC. | HOLLAND & KNIGHT LLP | $50K | H.R. 1577 - Treat and Reduce Obesity Act of 2021 (117th Cong.). H.R. 1577 - Treat and Reduce Obesity Act of 2021 (117th Cong.). |
| 2025-04-17 | NVO | NOVO NORDISK INC. | PUBLIC STRATEGIES WASHINGTON, INC. | $30K | Issues related to the coverage of obesity therapeutics |
| 2025-03-10 | NVO | NOVO NORDISK INC. | THE NICKLES GROUP, LLC | $0 | Issues related to prescription drugs. Issues related to tax policy. Issues related to prescription drugs. Issues related to tax policy. Issues related to prescription drugs. Issues related to tax policy. Issues related to prescription drugs. Issues related to tax policy. |
| 2025-02-20 | NVO | NOVO NORDISK INC. | CHECKMATE GOVERNMENT RELATIONS | $0 | Issues and legislation related to anti-obesity medications, drug pricing, and pharmaceutical supply chain. |
| 2025-01-22 | NVO | NOVO NORDISK INC. | WILLIAMS AND JENSEN, PLLC | $60K | Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158). Support for obesity drug coverage and access. Treat and Reduce Obesity Act and obesity treatment in COVID-19 relief; Medication affordability and access; general diabetes prevention; "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 4818, S. 2407. Public Law 118-47. American Relief Act (P.L. 118-158). Monitor general business tax issues. General issues related to patent protections. |
| 2025-01-21 | NVO | NOVO NORDISK INC. | AVOQ, LLC | $60K | Issues related to obesity; H.R. 4818/S. 2407, Treat and Reduce Obesity Act of 2023 Issues related to obesity H.R. 4818/S. 2407, Treat and Reduce Obesity Act of 2023 |
| 2025-01-21 | NVO | NOVO NORDISK INC. | TODD STRATEGY GROUP | $60K | Implementation of Inflation Reduction Act Pharmacy Benefit Manager Reform Health care supply chain 340B Treat and Reduce Obesity Act. |
| 2025-01-20 | NVO | NOVO NORDISK INC. | NVG, LLC | $80K | FY 2024 appropriations: LHHS Appropriations related to Medicare Part D coverage of anti-obesity medications. Issues related to Medicare coverage of Anti Obesity Medicines. H.R.4818 / S. 2407 - Treat and Reduce Obesity Act of 2023. Issues related to insulin. Issues related to pharmaceutical supply chain transparency and integrity. Issues relating to pharmaceutical drug pricing. Issues related to compounding and counterfeit medicines. |
| 2025-01-20 | NVO | NOVO NORDISK INC. | HOLLAND & KNIGHT LLP | $50K | H.R. 1577 - Treat and Reduce Obesity Act of 2021 (117th Cong.). H.R. 1577 - Treat and Reduce Obesity Act of 2021 (117th Cong.). |